As NHS waiting lists remain above 7 million treatment pathways and private healthcare costs continue to rise, increasing numbers of UK patients are exploring treatment abroad. This article examines the latest NHS backlog data, the impact of delays on orthopaedic patients and the reasons why accredited European hospitals are becoming an increasingly popular alternative. It also explores treatment costs, waiting times and how medical travel platforms are helping patients access faster, consultant-led care at competitive prices.

For many years, travelling abroad for medical treatment was viewed as a niche option, associated mainly with cosmetic procedures or specialist treatments unavailable in the UK. Today, the picture is different.

A growing number of UK patients are exploring treatment abroad for orthopaedic surgery, spinal procedures, diagnostics and other elective treatments. The primary driver is not tourism, it is access.

As NHS waiting lists remain above 7 million treatment pathways and millions of patients continue to experience delays in consultations, diagnostics and surgery, increasing numbers of people are asking a simple question: if treatment is available elsewhere, why continue waiting?

The NHS Backlog Remains a Reality

The Prime Minister has reported that waiting lists fell to around 7.1 million treatment pathways during 2026, the lowest level seen for several years, following record levels of elective activity. More than 18.4 million treatments and operations were delivered during 2025, the highest annual total in NHS history.

However, for patients, the headline figures do not always reflect lived experience. The median waiting time for treatment remains significantly above pre-pandemic levels and performance continues to fall far short of the NHS constitutional standard that 92% of patients should begin treatment within 18 weeks of referral. The standard has not been met since 2015.

For orthopaedic patients, this often translates into months of ongoing pain, reduced mobility and declining quality of life.

Diagnostics Are Often the First Bottleneck

Many patients assume they are waiting only for surgery. In reality, delays often begin much earlier.

Recent data showed that a record 1.92 million people in England were waiting for diagnostic tests such as MRI scans, CT scans and ultrasound examinations. More than 400,000 patients were waiting beyond the NHS six-week diagnostic target.

For patients with hip arthritis, knee arthritis, spinal disorders or sports injuries, delayed diagnostics can postpone every subsequent step in the treatment pathway. A patient cannot join a surgical waiting list until a diagnosis has been confirmed. As a result, many people experience delays before they even reach the point of discussing treatment options.

The Real Cost of Waiting

Waiting is often discussed as an administrative issue. For patients, it is much more personal.

A delayed hip replacement may mean another six months of restricted mobility. A postponed knee replacement may mean continuing pain medication, disrupted sleep and reduced independence. Delayed spinal surgery can affect employment, family life and mental wellbeing.

The impact is particularly significant for the UK’s more than four million self-employed workers, whose ability to earn an income may depend directly on their physical mobility and fitness. For many patients, the question eventually becomes whether the cost of waiting exceeds the cost of treatment.

Private Healthcare Is Not Always the Answer

Historically, patients seeking faster treatment often turned to UK private healthcare, and many that can afford to still do.

However, private healthcare costs have risen substantially over recent years. At the same time, private medical insurance premiums have increased sharply following the pandemic. Many people who previously benefited from employer-funded insurance lose access when they retire, while others find ongoing premiums increasingly difficult to justify.

For orthopaedic procedures, UK private treatment costs can be substantial.

At the current exchange rate, a total knee joint replacement typically costs €17,263, a total hip replacement typically costs €16,682 and a shoulder replacement costs €15,249. For many households, these costs create a second barrier even after NHS waiting lists become unacceptable.

Why Europe Is Attracting Attention

This is where treatment abroad enters the discussion.

Across many European healthcare markets, patients can access consultant-led treatment at accredited MMG hospitals for significantly lower prices than those commonly available within the UK private sector.

Once more in euros at the current exchange rate, MMG market analysis shows average European prices of approximately:

• €9,840 for total knee joint replacement surgery
• €9,512 for total hip replacement surgery
• €8,692 for shoulder replacement surgery
• €7,544 for spinal discectomy procedures

These figures represent savings ranging from approximately 27% to 38% compared with typical UK private healthcare prices, and in some parts of the EU the savings are significantly greater.

For patients paying directly for treatment, these differences can be significant. Importantly, patients are not simply purchasing a cheaper operation. They are often accessing shorter waiting times, consultant-led care and fixed-price treatment packages that provide greater cost certainty.

Treatment Abroad Is No Longer Unusual

Medical travel has become increasingly mainstream.

Reports suggest that hundreds of thousands of UK residents seek treatment abroad each year, driven by a combination of waiting times, affordability and access to specialist care. According to the ONS, that figure was 520,000 persons in 2025. Hip replacement surgery, knee replacement surgery and other elective procedures are among the treatments most commonly sought outside the UK.

This trend is likely to continue as patients become more comfortable researching healthcare options internationally.

Just as consumers routinely compare flights, hotels and insurance products online, patients are increasingly comparing hospitals, surgeons, treatment pathways and prices across multiple countries.

The Role of Medical Travel Platforms

The challenge for patients is knowing where to begin.

Navigating international healthcare independently can be complex. Understanding hospital accreditation, treatment inclusions, pricing structures and aftercare arrangements requires time and expertise.

This is where My Medical Gateway’s specialist medical travel platform provides value. Through MMG’s healthcare marketplace, patients can compare treatment options across MMG Accredited Healthcare Providers, review pricing, assess quality indicators and make informed decisions based on their own priorities.

Rather than relying on a single hospital recommendation, patients can compare providers based on price, location, treatment availability and clinical quality.

The Bottom Line

Patients are not choosing treatment abroad because they dislike the NHS. Most would prefer timely treatment close to home.

However, when waiting lists stretch into months, diagnostics are delayed and private healthcare costs become increasingly difficult to afford, alternative pathways become more attractive.

The combination of sustained NHS backlogs, rising UK private healthcare costs and the availability of lower-cost, high-quality treatment across Europe is reshaping patient behaviour. mFor many orthopaedic patients in 2026, treatment abroad is no longer viewed as an unusual option. It is increasingly viewed as a practical one.